METHODS: Here, we describe the case of a male patient with metastatic HCC. After failure of standard of care treatment with lenvatinib, sorafenib and ramucirumab fourth-line systemic therapy with atezolizumab and bevacizumab were applied leading to a phenomenal response. Immunohistochemical evaluations were compatible with Wnt/ß-catenin pathway activation and accompanying low T-cell infiltration as well as low PD-L1 score.
CONCLUSIONS: Patients with Wnt/ß-catenin activation may benefit from combination therapy with atezolizumab and bevacizumab regardless of potential predictive markers for immune checkpoint inhibition.
方法:这里,我们描述了一名男性转移性HCC患者的情况。lenvatinib标准治疗失败后,索拉非尼和雷莫西单抗四线全身治疗与阿特珠单抗和贝伐单抗一起应用,导致显著的缓解.免疫组织化学评估与Wnt/β-catenin途径激活和伴随的低T细胞浸润以及低PD-L1评分相容。
结论:Wnt/β-catenin激活的患者可能受益于阿特珠单抗和贝伐单抗的联合治疗,而不考虑免疫检查点抑制的潜在预测标志物。